Filana Therapeutics (FLNA) Appoints Jill M. Quigley to Its Board
Filana Therapeutics (FLNA) added Jill M. Quigley to its board. The company expects to start patient screening for its Phase 2a simufilam study in TSC-related epilepsy by Q1 2027, according to the company.
How this was made

The 30-second read
Why it matters
Board addition is a routine governance update with limited trading relevance.
Market read
Low relevance; no immediate price catalyst.
What to watch
Potential future clinical milestones (Phase 2a screening) may become more relevant than the appointment itself.
Background
Filana Therapeutics is a clinical-stage biotech developing simufilam for TSC-related epilepsy.
Ticker impact
Board appointment of Jill M. Quigley announced, indicating governance change.
likely little price movement as board changes are typically low impact.
Board appointments rarely move the stock unless tied to strategic shift; no new catalyst beyond the appointment.
Market effects
None significant; biotech sector unchanged.
None.
None.
Counterpoint
If investors view board changes as a signal of upcoming strategic moves, the stock could see modest upside.
Key entities
- CompanyFilana Therapeutics
Clinical-stage biotech developing simufilam.
- PersonJill M. Quigley
New board member.